BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
Executive Summary
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
You may also be interested in...
BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu
Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.
BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?
Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.
Coronavirus Update: With New Data, Don’t Count J&J Out Yet
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.